Kosan's work with polyketides looks interesting. So I'm creating this thread to spare the T/FIF thread too much chatter on the subject. KOSN's lock-up expiration agreements expired over a month before this was written. The only sale to date by insiders was bought by other insiders in a private placement. The latter being a director and the CEO, so a nice sign of support.
Kosan's technology for manufacturing polyketides in quantity could provide a near term source of funding for their drug discovery programs. |
